Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

Similar articles for PubMed (Select 21096084)

1.

Construction of signaling pathways and identification of drug effects on the liver cancer cell HepG2.

Alexopoulos LG, Melas IN, Chairakaki AD, Saez-Rodriguez J, Mitsos A.

Conf Proc IEEE Eng Med Biol Soc. 2010;2010:6717-20. doi: 10.1109/IEMBS.2010.5626246.

PMID:
21096084
2.

Deciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action.

Sun J, Zhao M, Jia P, Wang L, Wu Y, Iverson C, Zhou Y, Bowton E, Roden DM, Denny JC, Aldrich MC, Xu H, Zhao Z.

PLoS Comput Biol. 2015 Jun 17;11(6):e1004202. doi: 10.1371/journal.pcbi.1004202. eCollection 2015 Jun.

3.

Integrating genomics and proteomics data to predict drug effects using binary linear programming.

Ji Z, Su J, Liu C, Wang H, Huang D, Zhou X.

PLoS One. 2014 Jul 18;9(7):e102798. doi: 10.1371/journal.pone.0102798. eCollection 2014.

4.

Eukaryotic initiation factor 2α--a downstream effector of mammalian target of rapamycin--modulates DNA repair and cancer response to treatment.

Tuval-Kochen L, Paglin S, Keshet G, Lerenthal Y, Nakar C, Golani T, Toren A, Yahalom J, Pfeffer R, Lawrence Y.

PLoS One. 2013 Oct 25;8(10):e77260. doi: 10.1371/journal.pone.0077260. eCollection 2013.

5.

Expression profiling based on graph-clustering approach to determine colon cancer pathway.

Zhu XQ, Hu ML, Zhang F, Tao Y, Wu CM, Lin SZ, He FL.

J Cancer Res Ther. 2013 Jul-Sep;9(3):467-70. doi: 10.4103/0973-1482.119351.

6.

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.

Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, Ellul J, Kleinschmidt M, Kinross KM, Bowtell DD, Christensen JG, Hicks RJ, Johnstone RW, McArthur GA, Hannan RD, Phillips WA, Pearson RB.

Eur J Cancer. 2013 Dec;49(18):3936-44. doi: 10.1016/j.ejca.2013.08.007. Epub 2013 Sep 3.

PMID:
24011934
7.

Reconstruction of cellular signal transduction networks using perturbation assays and linear programming.

Knapp B, Kaderali L.

PLoS One. 2013 Jul 30;8(7):e69220. doi: 10.1371/journal.pone.0069220. Print 2013.

8.

Structural and logical analysis of a comprehensive hedgehog signaling pathway to identify alternative drug targets for glioma, colon and pancreatic cancer.

Chowdhury S, Pradhan RN, Sarkar RR.

PLoS One. 2013 Jul 23;8(7):e69132. doi: 10.1371/journal.pone.0069132. Print 2013.

9.

Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.

Arsenault RJ, Kogut MH, He H.

Cell Signal. 2013 Nov;25(11):2246-54. doi: 10.1016/j.cellsig.2013.07.014. Epub 2013 Jul 19.

PMID:
23876795
10.

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

Browne BC, Hochgräfe F, Wu J, Millar EK, Barraclough J, Stone A, McCloy RA, Lee CS, Roberts C, Ali NA, Boulghourjian A, Schmich F, Linding R, Farrow L, Gee JM, Nicholson RI, O'Toole SA, Sutherland RL, Musgrove EA, Butt AJ, Daly RJ.

FEBS J. 2013 Nov;280(21):5237-57. doi: 10.1111/febs.12441. Epub 2013 Aug 19.

PMID:
23876235
11.

Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells.

Fei SJ, Zhang XC, Dong S, Cheng H, Zhang YF, Huang L, Zhou HY, Xie Z, Chen ZH, Wu YL.

PLoS One. 2013 Jul 16;8(7):e69104. doi: 10.1371/journal.pone.0069104. Print 2013.

12.

Integrating Bayesian variable selection with Modular Response Analysis to infer biochemical network topology.

Santra T, Kolch W, Kholodenko BN.

BMC Syst Biol. 2013 Jul 6;7:57. doi: 10.1186/1752-0509-7-57.

13.

Layered signaling regulatory networks analysis of gene expression involved in malignant tumorigenesis of non-resolving ulcerative colitis via integration of cross-study microarray profiles.

Fan S, Pan Z, Geng Q, Li X, Wang Y, An Y, Xu Y, Tie L, Pan Y, Li X.

PLoS One. 2013 Jun 25;8(6):e67142. doi: 10.1371/journal.pone.0067142. Print 2013.

14.

Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.

Ou DL, Lee BS, Chang YC, Lin LI, Liou JY, Hsu C, Cheng AL.

PLoS One. 2013 Jun 20;8(6):e66589. doi: 10.1371/journal.pone.0066589. Print 2013.

15.

Redundancy control in pathway databases (ReCiPa): an application for improving gene-set enrichment analysis in Omics studies and "Big data" biology.

Vivar JC, Pemu P, McPherson R, Ghosh S.

OMICS. 2013 Aug;17(8):414-22. doi: 10.1089/omi.2012.0083. Epub 2013 Jun 11.

16.

Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.

Sooman L, Ekman S, Andersson C, Kultima HG, Isaksson A, Johansson F, Bergqvist M, Blomquist E, Lennartsson J, Gullbo J.

Cancer Chemother Pharmacol. 2013 Aug;72(2):329-40. doi: 10.1007/s00280-013-2197-7. Epub 2013 Jun 5.

PMID:
23736154
17.

Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer.

Yang Y, Li H, Hou S, Hu B, Liu J, Wang J.

Oncol Rep. 2013 Aug;30(2):596-614. doi: 10.3892/or.2013.2514. Epub 2013 Jun 3.

PMID:
23733047
18.

Simultaneous identification of multiple driver pathways in cancer.

Leiserson MD, Blokh D, Sharan R, Raphael BJ.

PLoS Comput Biol. 2013;9(5):e1003054. doi: 10.1371/journal.pcbi.1003054. Epub 2013 May 23.

19.

Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.

Chen G, Qiu H, Ke SD, Hu SM, Yu SY, Zou SQ.

World J Gastroenterol. 2013 Apr 28;19(16):2481-91. doi: 10.3748/wjg.v19.i16.2481.

20.

GRK2 negatively regulates IGF-1R signaling pathway and cyclins' expression in HepG2 cells.

Wei Z, Hurtt R, Gu T, Bodzin AS, Koch WJ, Doria C.

J Cell Physiol. 2013 Sep;228(9):1897-901. doi: 10.1002/jcp.24353.

PMID:
23460259
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk